Management of restless legs syndrome in patients on dialysis.

Drugs
Miklos Z MolnarIstvan Mucsi

Abstract

Restless legs syndrome (RLS) is characterised by an urge to move the legs, uncomfortable sensations in the legs and worsening of these symptoms during rest with at least temporary relief brought on by activity. RLS occurs in 3-15% of the general population and in 10-30% of patients on maintenance dialysis. RLS may lead to severe sleep onset or maintenance insomnia, and greatly impaired quality of life. Current recommendations suggest dopaminergic therapy (levodopa or dopamine receptor agonists: pramipexol, ropinirole, pergolide or cabergoline) as the first-line treatment for RLS. This group of medications is effective in reducing RLS symptoms in the general population; limited information is available on the effect of these drugs in patients with renal failure. However, it must be noted that most published studies in uraemic patients had short treatment periods and insufficient statistical power because of small sample size. Frequent adverse effects of levodopa, seen mainly with continuous use, may limit its use significantly. Rebound and augmentation, problems relatively frequently seen with levodopa, seem to be less prevalent with the use of dopamine receptor agonists, although properly designed comparative trials are still n...Continue Reading

References

Sep 1, 1992·The Japanese Journal of Psychiatry and Neurology·J HoriguchiT Sukegawa
Feb 1, 1992·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·J L HolleyR Rault
Dec 1, 1991·Biological Psychiatry·T TeraoK Abe
Dec 1, 1987·Journal of Neurology, Neurosurgery, and Psychiatry·R Peled, P Lavie
Aug 1, 1986·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·D BoghenJ Montplaisir
Aug 1, 1987·The International Journal of Neuroscience·R SandykC R Bamford
Mar 1, 1987·Archives of General Psychiatry·M J Garvey, G D Tollefson
Jun 1, 1984·Acta Neurologica Scandinavica·P MontagnaE Lugaresi
Feb 11, 1984·British Medical Journal·W TelstadR Nyberg-Hansen
Oct 3, 1981·British Medical Journal·R Stout, R D Hunter
Oct 3, 1981·British Medical Journal·D J ReadM A Nassim
Feb 13, 1982·British Medical Journal·W Braude, T Barnes
Nov 1, 1982·Archives of Neurology·S Akpinar
Nov 1, 1995·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·S WalkerM H Kryger
Sep 1, 1995·Movement Disorders : Official Journal of the Movement Disorder Society·A S Walters
Mar 1, 1996·Journal of Sleep Research·J KaprioM Koskenvuo
Sep 1, 1996·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·J W WinkelmanJ M Lazarus
Oct 1, 1996·Journal of the Neurological Sciences·R Bakshi
Dec 1, 1996·Neurology·W Ondo, J Jankovic
Jan 1, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·J MontplaisirP Lespérance
Apr 1, 1997·Clinical Neuropharmacology·C H Adler
Feb 20, 1998·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·V Collado-SeidelC Trenkwalder
Apr 29, 1998·Mayo Clinic Proceedings·J B Gross
Jun 5, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·J D O'Sullivan, A J Hughes
Jun 5, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·J WinkelmannC Trenkwalder
Jun 11, 1998·Mayo Clinic Proceedings·S C LinP A Fredrickson
Apr 2, 1999·Neurology·J MontplaisirB Gomez-Mancilla
Apr 7, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·M MichaudJ Montplaisir
Jun 10, 2000·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·R L BenzD D Peterson
Jul 25, 2000·Archives of Internal Medicine·B PhillipsC Purvis
Sep 29, 2000·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·D S HuiP K Li

❮ Previous
Next ❯

Citations

Jul 2, 2010·Sleep & Breathing = Schlaf & Atmung·Deniz TuncelAytac Dinc
Sep 16, 2008·CNS Drugs·Claudine M Baldwin, Gillian M Keating
Jul 20, 2012·Expert Opinion on Drug Metabolism & Toxicology·Stefano de BiaseGian Luigi Gigli
Sep 12, 2015·Seminars in Nephrology·Marta NovakMark Unruh
Oct 4, 2016·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Jennifer S SchererFrank Brennan
Jan 25, 2018·International Urology and Nephrology·Ji-Hyung ChoJun Chul Kim
Dec 18, 2008·The International Journal of Artificial Organs·G C Kosmadakis, J F Medcalf
Feb 27, 2017·Clinical Pharmacokinetics·Aravind MitturNishit B Modi
Aug 7, 2019·Harvard Review of Psychiatry·Vinícius Dokkedal-SilvaMonica Levy Andersen
Nov 4, 2020·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Yasaman SafarpourBahman Jabbari

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.